Adlon Therapeutics' Adhansia XR, or methylphenidate HCl extended release, has been approved by the FDA as a treatment for patients age 6 and older with attention-deficit/hyperactivity disorder. The decision was backed by data from four studies, in which patients who were treated with Adhansia XR significantly improved versus placebo use.
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.